Elamipretide Trial Planned for Patients With Vision, Heart Problems

Elamipretide Trial Planned for Patients With Vision, Heart Problems

291476

Elamipretide Trial Planned for Patients With Vision, Heart Problems

Stealth BioTherapeutics is planning a Phase 2a clinical trial of elamipretide (SS-31) as a treatment for people with vision loss and/or heart disease associated with Friedreich’s ataxia (FA). The company expects to use data from this study — planned to start later this year — in designing a pivotal clinical trial, which will confirm the candidate therapy’s safety and efficacy before seeking regulatory approval. “We are poised to progress our planned clinical expansion into rare metabolic…

You must be logged in to read/download the full post.